GSK plc (GSK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $101.13B
Last updated: Nov 17, 2026 at 11:06 AM ET
GSK plc (GSK) Financials: Revenue, Profit and Cash Flow
GSK reported revenue of GBP 32.67B for the fiscal year ended Dec 31, 2025, up 4.1% from the year before. That year, net income was GBP 5.72B with a net margin of 17.5%, operating cash flow was GBP 7.74B and free cash flow was GBP 6.39B. The quarter ended Sep 30, 2026 had revenue of GBP 8.82B and net income of GBP 1.53B.
Revenue and Margins
The operating margin was 24.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from GBP 27.89B, a compound annual rate of 1.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 32.67B | +4.1% | 72.4% | 24.3% | 17.5% |
| Dec 2024 | 31.38B | +3.5% | 71.2% | 12.8% | 8.2% |
| Dec 2023 | 30.33B | +3.4% | 71.8% | 22.2% | 16.2% |
| Dec 2022 | 29.32B | +18.7% | 67.4% | 21.9% | 51.0% |
| Dec 2021 | 24.70B | +1.4% | 66.9% | 17.6% | 17.8% |
| Dec 2020 | 24.35B | -27.8% | 67.4% | 24.6% | 23.6% |
| Dec 2019 | 33.75B | +9.5% | 64.9% | 20.6% | 13.8% |
| Dec 2018 | 30.82B | +2.1% | 66.8% | 17.8% | 11.8% |
| Dec 2017 | 30.19B | +8.2% | 65.7% | 13.5% | 5.1% |
| Dec 2016 | 27.89B | N/A | 66.7% | 9.3% | 3.3% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 121.7% from the year before. In the quarter ended Sep 2026, net income fell 23.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.67B | 31.38B | 30.33B | 29.32B | 24.70B | 24.35B | 33.75B | 30.82B | 30.19B | 27.89B |
| Cost of revenue | 9.02B | 9.05B | 8.56B | 9.55B | 8.16B | 7.93B | 11.86B | 10.24B | 10.34B | 9.29B |
| Gross profit | 23.65B | 22.33B | 21.76B | 19.77B | 16.53B | 16.43B | 21.89B | 20.58B | 19.84B | 18.60B |
| Research and development | 7.53B | 6.40B | 6.22B | 5.49B | 5.02B | 4.79B | 4.57B | 3.89B | 4.48B | 3.63B |
| Operating income | 7.93B | 4.02B | 6.75B | 6.43B | 4.36B | 5.98B | 6.96B | 5.48B | 4.09B | 2.60B |
| Net income | 5.72B | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B | 4.64B | 3.62B | 1.53B | 912.00M |
| EBITDA | 10.40B | 6.67B | 9.15B | 8.56B | 6.49B | 8.07B | 9.43B | 7.35B | 6.18B | 4.43B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.82B | 8.41B | 7.63B | 8.62B | 8.55B | 7.99B | 7.52B | 8.12B | 8.01B | 7.88B | 7.36B | 8.05B |
| Gross profit | 6.56B | 6.14B | 5.75B | 5.96B | 6.29B | 5.82B | 5.58B | 5.56B | 5.62B | 5.76B | 5.39B | 5.63B |
| Operating income | 2.55B | 481.00M | 2.29B | 1.51B | 2.59B | 2.02B | 2.22B | 696.00M | 189.00M | 1.65B | 1.49B | 573.00M |
| Net income | 1.53B | 435.00M | 1.74B | 636.00M | 2.01B | 1.44B | 1.62B | 414.00M | -58.00M | 1.17B | 1.05B | 350.00M |
Balance Sheet
As of Dec 2025, total debt of GBP 17.03B exceeded cash and equivalents by 13.63B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 61.12B | 59.46B | 75.22B | 60.15B | 107.14B | 109.95B | 105.57B | 58.07B | 56.38B | 59.08B |
| Current assets | 17.51B | 17.00B | 23.77B | 20.77B | 25.29B | 27.68B | 25.82B | 16.93B | 15.91B | 16.71B |
| Cash and equivalents | 3.40B | 3.69B | 3.74B | 3.72B | 5.79B | 8.60B | 6.24B | 3.87B | 3.83B | 4.90B |
| Total liabilities | 45.16B | 46.38B | 58.91B | 50.05B | 78.23B | 81.50B | 81.25B | 54.39B | 52.89B | 54.12B |
| Short-term debt | 3.01B | 2.35B | 3.59B | 3.95B | 4.88B | 5.09B | 9.16B | 5.79B | 2.83B | 4.13B |
| Long-term debt | 14.02B | 13.70B | 14.15B | 17.04B | 20.57B | 23.43B | 22.58B | 20.23B | 14.22B | 14.62B |
| Shareholder equity | 16.38B | 13.67B | 17.01B | 10.60B | 20.39B | 19.94B | 15.11B | 3.78B | 3.49B | 4.96B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 72.18B | 61.37B | 82.91B | 61.12B | 82.58B | 81.20B | 78.35B | 59.46B | 58.05B | 73.40B | 73.91B | 75.22B |
| Total liabilities | 53.69B | 44.29B | 59.93B | 45.16B | 61.37B | 61.53B | 60.73B | 46.38B | 44.60B | 55.99B | 57.20B | 58.91B |
| Cash and equivalents | 2.95B | 3.09B | 4.54B | 3.40B | 4.44B | 4.93B | 5.76B | 3.69B | 3.19B | 3.74B | 3.52B | 3.74B |
| Shareholder equity | 18.88B | 17.54B | 23.54B | 16.38B | 21.74B | 20.27B | 18.27B | 13.67B | 14.01B | 18.17B | 17.48B | 17.01B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 82.6% of operating cash flow. Dividends came to 40.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.74B | 6.55B | 6.77B | 7.40B | 7.95B | 8.44B | 8.02B | 8.42B | 6.92B | 6.50B |
| Capital expenditures | 1.35B | 2.98B | 2.34B | 2.26B | 2.93B | 2.24B | 2.16B | 1.80B | 2.20B | 2.35B |
| Free cash flow | 6.39B | 3.57B | 4.42B | 5.14B | 5.02B | 6.20B | 5.86B | 6.63B | 4.72B | 4.14B |
| Dividends paid | 2.56B | 2.44B | 2.25B | 3.47B | 4.00B | 3.98B | 3.95B | 3.93B | 3.91B | 4.85B |
| Investing cash flow | -4.23B | -1.23B | -1.59B | -8.77B | -1.78B | 2.16B | -5.35B | -1.55B | -1.44B | -1.27B |
| Financing cash flow | -3.69B | -4.73B | -5.64B | 823.00M | -7.59B | -10.13B | -1.84B | -6.39B | -6.38B | -6.39B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.79B | 2.54B | 1.14B | 2.04B | 3.03B | 2.10B | 1.15B | 2.33B | 2.15B | 1.11B | 1.19B | 3.62B |
| Capital expenditures | 372.39M | 328.95M | 443.00M | 560.25M | 428.37M | 633.00M | 448.00M | 1.14B | 842.00M | 442.00M | 314.45M | 587.28M |
| Free cash flow | 2.41B | 2.21B | 698.00M | 1.48B | 2.60B | 1.46B | 697.00M | 1.19B | 1.31B | 671.00M | 876.15M | 3.03B |
Frequently Asked Questions About GSK
What is GSK's annual revenue?
GSK reported revenue of GBP 32.67B for the fiscal year ended Dec 31, 2025.
How fast is GSK's revenue growing?
Revenue was up 4.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.7%.
Is GSK profitable?
Yes. GSK reported net income of GBP 5.72B for the fiscal year ended Dec 31, 2025, with a net margin of 17.5%.
How much free cash flow does GSK generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of GBP 7.74B minus capital expenditures of GBP 1.35B produced free cash flow of GBP 6.39B.
How much debt does GSK have?
The balance sheet dated Dec 31, 2025 reported long-term debt of GBP 14.02B, short-term debt of GBP 3.01B and cash and equivalents of GBP 3.40B.
GSK pages: Overview, Dividends, Financials, Valuation, Competitors, Government Contracts